AI Article Synopsis
- The PARTNER 3 and Evolut LRT trials have established the foundation for using transcatheter aortic valve implantation in low-risk patients.
- Concerns remain regarding the durability, long-term outcomes, and potential complications associated with this procedure.
- Widespread adoption of this treatment in low-risk patients may not be justified until these issues are adequately addressed.
Article Abstract
The PARTNER 3 and Evolut LRT trials have provided the evidence base for transcatheter aortic valve implantation in low-risk patients. However, there are still issues with durability, long-term follow up and complications before their widespread use can be considered appropriate in this group.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.12968/hmed.2020.0059 | DOI Listing |
Publication Analysis
Top Keywords
transcatheter aortic
8
aortic valve
8
valve implantation
8
implantation inappropriate
4
inappropriate low-risk
4
low-risk young
4
young patients
4
patients perspective
4
perspective partner
4
partner evolut
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!